On a mission to eradicate neurodegenerative diseases through the precision targeting of toxic misfolded protein aggregates.
Our lead candidates ABY-1125 and ABY-1220 are a monoclonal antibodies (mAbs) that selectively bind to the toxic misfolded forms of amyloid-beta. In preclinical studies, ABY-1125 has shown significantly greater selectivity for toxic oligomers in AD brain samples than other amyloid-targeting antibodies therapies currently in clinical development. Moreover, our data confirm that ABY-1125 and ABY-1220 bind to epitopes that are only present in oligomers and that no other mAbs bind to.
Company Details
- Employees
- 7
- Founded
- -
- Address
- 855 Boylston St,
- in****@****bio.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- aby-bio.com
- Keywords
- Immunology, CNS, Neurodegenerative Disease, Alzheimer's Disease, Neurodegeneration, Biotechnology, Dementia, Alzheimer's Diagnostics.
- HQ
- Boston, Massachusetts
Abyssinia Biosciences Questions
Abyssinia Biosciences's website is aby-bio.com
Abyssinia Biosciences's LinkedIn profile is https://www.linkedin.com/company/aby-bio
Abyssinia Biosciences has
7 employees.
View email and phone details for 7
employees at Abyssinia Biosciences.
Abyssinia Biosciences's industry is
Biotechnology Research
Abyssinia Biosciences's top competitors are
Crinetics Pharmaceuticals,
Esperion,
Juvena Therapeutics,
Rejuvenate Biomed,
Raven (Ra Ventures),
Endurance Bio Inc.,
Nucyrna Therapeutics,
Alloy Therapeutics, Inc.,
Insight Partners,
Ra Capital Management.
Abyssinia Biosciences's support email address is info@aby-bio.com
Abyssinia Biosciences's categories are Biotechnology Research
Abyssinia Biosciences's founding year is 2017
